News from celsion corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 24, 2016, 08:00 ET Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose...


May 16, 2016, 08:00 ET Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and...


May 09, 2016, 08:00 ET Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016

Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended...


May 02, 2016, 08:00 ET Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose ...


Apr 26, 2016, 08:00 ET Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its...


Apr 19, 2016, 08:00 ET Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil®

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with...


Apr 12, 2016, 08:00 ET Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian...


Mar 30, 2016, 08:00 ET Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and...


Mar 23, 2016, 08:00 ET Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016

Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and...


Mar 16, 2016, 04:35 ET Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® at the AACR Annual Meeting 2016

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that its preclinical data for GEN-1 in combination with...


Mar 07, 2016, 08:00 ET Celsion Corporation Announces Launch of the OPTIMA Study in China

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Mar 01, 2016, 08:00 ET Celsion Corporation Announces Issuance of Key U.S. Patent Covering its Novel TheraSilence™ RNA Program

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Feb 12, 2016, 08:00 ET Celsion Corporation Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update

Celsion Corporation (Celsion) (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer...


Jan 07, 2016, 08:00 ET Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer

Celsion Corporation (NASDAQ: CLSN), today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant...


Dec 17, 2015, 08:00 ET Celsion Announces Appointment of Two New Members to Its Board of Directors

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Dec 16, 2015, 08:00 ET Celsion Receives CFDA Approval to Conduct the OPTIMA Study in China

Celsion Corporation (NASDAQ: CLSN) today announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug...


Dec 14, 2015, 08:00 ET Celsion Announces Presentation of DIGNITY Phase I/II ThermoDox® Data at the 2015 San Antonio Breast Cancer Symposium

Celsion Corporation (NASDAQ: CLSN) today announced the presentation of results from its ongoing Phase I/II US DIGNITY Study of ThermoDox® in...


Nov 24, 2015, 08:00 ET Celsion Corporation to Present at the LD Micro Main Event Investor Conference

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Nov 11, 2015, 06:00 ET Celsion Corporation Announces Dual Listing on the Tel Aviv Stock Exchange

Celsion Corporation (NASDAQ: CLSN), a fully integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Nov 05, 2015, 08:00 ET Celsion Corporation Reports Third Quarter 2015 Financial Results and Provides Business Update

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended September 30, 2015...


Nov 03, 2015, 08:00 ET Celsion Corporation Names Edwin De Wit, M.D. as Senior Vice President and Head of Medical, Europe

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...


Nov 02, 2015, 08:00 ET Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate HCC at the 2nd Asian Conference on Tumor Ablation (ACTA)

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study,...


Oct 29, 2015, 08:00 ET Celsion Corporation to Hold Third Quarter 2015 Financial Results Conference Call on Thursday, November 5, 2015

Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2015 financial results...


Oct 15, 2015, 08:00 ET Celsion to Host Research and Development Day on October 27, 2015

Celsion Corporation (NASDAQ: CLSN) today announced that it will host a Research and Development (R&D) Day for investors and analysts on Tuesday,...


Oct 12, 2015, 08:00 ET Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® for Ovarian Cancer

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today reported data from a large preclinical study of the Company's GEN-1...